12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Daclatasvir: Phase IIb data

Interim data from 41 treatment-naïve patients with chronic HCV genotype 1 infection in the double-blind, international Phase IIb D-LITE trial showed that 90% (n=37) of patients achieved a protocol defined response (PDR) while receiving once-weekly 180 µg subcutaneous PEG-interferon lambda plus once-daily 60 mg oral daclatasvir and ribavirin. PDR was defined as HCV RNA levels below the limit of quantification (<=25 IU/mL) at week 4 and undetectable HCV RNA levels (<25 IU/mL) at week 12. Achieving a PDR qualified a patient to complete 24 weeks of therapy. Of the 37 patients, 76% achieved an SVR defined as undetectable HCV RNA levels 12 weeks after completing 24 weeks of treatment with...

Read the full 528 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >